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Obesity is a major risk factor in the development of chronic
renal failure. Rimonabant, a cannabinoid CB1 receptor
antagonist, improves body weight and metabolic disorders;
however, its effect on mortality and chronic renal failure
associated with obesity is unknown. Obese Zucker rats
received either rimonabant or vehicle for 12 months and
were compared to a pair-fed but untreated group of obese
rats. Mortality in the obese rats was significantly reduced by
rimonabant along with a sustained decrease in body weight,
transient reduction in food intake, and an increase in plasma
adiponectin. This was associated with significant reduction in
plasma total cholesterol, low-density lipoprotein cholesterol/
high-density lipoprotein cholesterol ratio, triglycerides,
glucose, norepinephrine, plasminogen activator inhibitor 1,
and preservation of pancreatic weight and b-cell mass index.
The cannabinoid antagonist attenuated the increase in
proteinuria, urinary N-acetylglucosaminidase excretion,
plasma creatinine, and urea nitrogen levels while improving
creatinine clearance. Renal hypertrophy along with
glomerular and tubulointerstitial lesions were reduced by
rimonabant. Although the drug did not modify
hemodynamics, it normalized the pressor response to
angiotensin II. Our study suggests that in a rat model of
chronic renal failure due to obesity, rimonabant preserves
renal function and increases survival.
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Metabolic disorders and obesity are considered as major risk
factors in the development of chronic kidney failure and
ultimately end-stage renal diseases.1 Obesity alone is an
important predictor of shortened longevity and is associated
with the progression of renal disease.2 The greater incidence
of renal failure in the obese population results from several
factors including high glomerular filtration rate, altered renal
hemodynamics, adipocyte-derived proinflammatory cyto-
kines, and dyslipidemia.3–6 For instance, a negative correla-
tion has been established between triglycerides and creatinine
clearance, and hypertriglyceridemia increases the risk of
developing renal failure.7 Improvement of lipid profile
achieved by 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitors in dyslipidemic patients with chronic renal
failure has been reported to ameliorate creatinine clearance.8
Moreover, in animal models, hyperlipidemia resulting from
either high-fat diet or genetic modification has been
documented to promote chronic renal injury.9–11
Several reports have indicated that overactivation of the
endocannabinoid system contributes to the pathogenesis of
obesity and metabolic disorders through the stimulation of
the cannabinoid CB1 receptor subtype.12–15 This system plays
a role in the physiological regulation of energy balance, food
intake, and lipid and glucose metabolism through the
cannabinoid CB1 receptors located both at the central and
peripheral levels. Indeed, CB1 receptor-deficient mice display
a lean phenotype and are resistant to diet-induced obesity.16
Moreover, rimonabant, a selective CB1 receptor antagonist,
produced a sustained weight loss in obese animals, which was
associated with a transient reduction in food intake.
Metabolic abnormalities linked with established obesity were
corrected by rimonabant, including a near normalization of
lipid profile, plasma insulin, and leptin levels.15 These effects
are mediated by the chronic blockade of CB1 receptors, as the
antiobesity effect of rimonabant was no longer observed in
CB1 knockout mice.16 In line with these experimental results,
rimonabant has demonstrated its efficacy in reducing body
weight and cardiometabolic risk factors in obese patients,
including significant improvements in waist circumference,
high-density lipoprotein (HDL) cholesterol, triglycerides,
and insulin resistance.17–20
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Although the antiobesity effect of rimonabant is well
documented, its effect on renal failure and mortality
associated with obesity is unknown. Therefore, the specific
aim of this study was to determine whether, in addition to
improving metabolic function, long-term treatment with
rimonabant reduces the development of chronic renal failure,
and hence prolongs longevity in obese fa/fa Zucker rats. This
strain is characterized by hyperphagia, obesity, dyslipidemia,
and type II diabetes, resulting from a mutation of the leptin
receptor-encoding gene, which impairs feeding behavior. As a
consequence, these obese animals are prone to develop
chronic renal failure and display a reduced lifespan relative to
their lean controls.
RESULTS
Body weight and food intake
At 12 weeks of age, fa/fa Zucker rats displayed a greater body
weight than age-matched lean fa/þ Zucker rats (Figure 1a).
Body weight for both strains continued to increase and
reached a plateau after 6 months of treatment, after which it
remained stable for the following 3 months. Chronic
administration of rimonabant produced a dose-dependent
and sustained decrease in body weight gain, which was
statistically significant at 10 mg/kg/day. This antiobesity effect
was associated with a transient reduction in food intake
which attained a similar value to that measured in the lean
fa/þ controls (Figure 1b). Food intake returned to baseline
after 8 weeks of treatment with rimonabant at 10 mg/kg/day.
The pair-feeding protocol limited the body weight gain in
fa/fa Zucker rats in a similar manner. After 9 months of
treatment, the general health status of obese fa/fa Zucker rats
(12-month old) began to deteriorate as they reduced their
food intake and hence lost weight. At the end of the study
(12-month treatment) fa/fa Zucker rats could no longer be
considered as hyperphagic, since they exhibited a lower food
consumption than fa/þ Zucker rats. Chronic administration
of rimonabant maintained overall food intake until the end
of the study period and prevented the secondary body weight
loss observed after 12 months in vehicle-treated fa/fa Zucker
group.
Survival
Nontreated obese fa/fa Zucker rats started to die after 9
months of monitoring with a mortality rate of 64% after 1
year, whereas mortality was limited to 4% in age-matched
control lean Zucker rats (Figure 2). Rimonabant treatment
postponed the onset of mortality significantly in a dose-
dependent manner. After 1 year of treatment with rimona-
bant, the mortality rate was significantly reduced to 28%
(Po0.05) and 20% (Po0.05) at 3 and 10 mg/kg/day,
respectively. Although the mortality rate in the pair-feeding
group was circumscribed to 33%, it did not reach statistical
significance as the onset of mortality occurred earlier, after 5
months of food restriction.
To avoid a bias due to a difference of mortality between
groups beyond 9 months of treatment, the effects of
rimonabant on the metabolic abnormalities were investigated
at 9 months, and those on end-stage renal disease at 12 months.
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Figure 1 | Effects of rimonabant, 3 and 10 mg/kg/day p.o., and
pair-feeding on the (a) body weight (b) and food intake of obese
fa/fa Zucker rats in comparison with control lean fa/þ Zucker
rats over a 12-month treatment period. Values are expressed as
means7s.e.m. Statistical analysis was performed using two-way
ANOVA followed by Newman–Keuls post hoc test. Body weight gain
was significantly (Po0.05) reduced by rimonabant 10 mg/kg/day and
pair-feeding from 2 weeks to 9 months and 8 months of treatment,
respectively, in comparison with vehicle-treated group. Hyperphagia
was suppressed transiently and dose-dependently by rimonabant.
This reduction in food intake remained significant (Po0.05) up to 2
and 6 weeks after initiating the treatment with rimonabant at 3 and
10 mg/kg/day, respectively. *Po0.05 rimonabant 10 mg/kg vs obese
fa/fa-vehicle; #Po0.05 rimonabant 3 mg/kg vs obese fa/fa-vehicle;
yPo0.05 pair-feeding vs obese fa/fa-vehicle.
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Figure 2 | Effects of rimonabant, 3 and 10 mg/kg/day p.o., and
pair-feeding on the survival rate (%) of obese fa/fa Zucker rats in
comparison with control lean fa/þ Zucker rats over a 12-month
treatment period. Statistical analysis was performed with a log-rank
test. *Po0.05 vs vehicle-treated obese fa/fa Zucker rats.
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Metabolic disorders
Total plasma cholesterol, low-density lipoprotein (LDL)
cholesterol, triglycerides, and nonesterified fatty acids levels
were significantly elevated in obese fa/fa Zucker rats in
comparison with lean fa/þ Zucker rats (Figure 3). After 9
months of treatment, rimonabant produced a dose-depen-
dent reduction in these plasma lipid elevations and normal-
ized LDL-cholesterol/HDL-cholesterol ratio. Overall, the
pair-feeding protocol was also effective in reducing these
plasma lipid abnormalities, but less so than rimonabant at
10 mg/kg/day.
At 9 months, plasma adiponectin levels were significantly
lowered in obese fa/fa Zucker rats in comparison with the
lean controls. Although rimonabant at 10 mg/kg/day slightly
increased plasma adiponectin levels, it did not reach
statistical significance. However, this increase was found to
be significant after 6 months (Figure 4). Similar effects were
obtained in the pair-fed group.
Untreated obese fa/fa Zucker rats displayed a slight
hyperglycemia, which was significantly reduced only by
rimonabant at 10 mg/kg/day (Table 1). Fasting plasma insulin
and glucagon levels were moderately elevated in obese
animals and were not significantly modified by rimonabant.
In the pair-feeding group, plasma insulin levels tended to be
more elevated and glucagonaemia significantly lowered. The
increase in pancreas weight found in obese fa/fa Zucker rats
at 12 months was prevented by rimonabant 10 mg/kg/day
(Table 1). In addition, insulin immunostaining of pancreas
cross-sections revealed a significant reduction in b-cell mass
index and b-islet number in obese fa/fa Zucker rats, which
were preserved by rimonabant at 10 mg/kg/day (Table 1 and
Figure 5).
Regarding the plasma catecholamines levels, norepinephr-
ine was significantly increased in obese fa/fa Zucker rats and
was nearly normalized by rimonabant at 3 and 10 mg/kg/day,
but not by the pair-feeding protocol (Figure 6). Plasma
epinephrine levels did not differ between lean and obese
animals, and remained unchanged after treatment (data not
shown).
Hemodynamics
At 12 months, the surviving fa/fa Zucker-vehicle rats
presented, under anesthesia, a slight increase in arterial
pressure, which reached significance only for the systolic
pressure (Table 2). No differences in heart rate, left
ventricular pressure, and dP/dtmax were detected in obese
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Figure 3 | Effects of rimonabant, 3 and 10 mg/kg/day p.o., and pair-feeding, on (a) plasma triglycerides, (b) cholesterol,
(c) LDL-cholesterol, (d) LDL-cholesterol/HDL-cholesterol ratio, (e) non-esterified fatty acids in obese fa/fa Zucker rats in
comparison with control lean fa/þ Zucker rats after 9 months of chronic treatment. Values are expressed as means7s.e.m. Statistical
analysis was performed using Kruskal–Wallis test. *Po0.05 vs vehicle-treated obese fa/fa Zucker rats; no. Po0.05 rimonabant 10 mg/kg
vs pair-feeding.
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fa/fa Zucker rats compared to their lean controls. Hemo-
dynamics was not affected by chronic administration of
rimonabant or pair-feeding (Table 2). Intravenous injection
of angiotensin II (30 and 100 ng/kg) resulted in a dose-
dependent increase in mean arterial pressure, which was
enhanced in obese fa/fa Zucker rats in comparison with the
lean controls. This exaggerated pressor response to angio-
tensin II was normalized in the 10 mg rimonabant-treated
group, but not in the pair-fed group (Figure 7). Cardiac mass
expressed as function of body weight was not significantly
increased in obese animals, and remained unaltered by the
treatments (Table 2). Depressed renal blood flow observed in
obese fa/fa Zucker rats was not significantly improved by
rimonabant or pair-feeding.
Renal function
In comparison with lean fa/þ Zucker rats, obese fa/fa
Zucker rats developed a progressive and severe proteinuria
with aging together with a significant increase in plasma
creatinine and urea levels, and decrease in creatinine
clearance (Figures 8 and 9). Chronic administration of
rimonabant significantly delayed in a dose-dependent
manner the increase in proteinuria (Figure 8). The pair-fed
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Figure 4 | Effects of rimonabant, 3 and 10 mg/kg/day p.o., and
pair-feeding, on plasma adiponectin in obese fa/fa Zucker rats in
comparison with control lean fa/þ Zucker rats after 6 and 9
months of chronic treatment. Values are expressed as
means7s.e.m. Statistical analysis was performed using one-way
ANOVA followed by a Newman–Keuls post hoc test. *Po0.05 vs
vehicle-treated obese fa/fa Zucker rats; #Po0.05 rimonabant 10 mg/kg
vs pair-feeding.
Table 1 | Effects of rimonabant (3 and 10 mg/kg/day) and pair-feeding on fasting plasma glucose, insulin, glucagon, pancreas
weight, b-cell mass index, and b-islets number in obese fa/fa Zucker rats in comparison with control lean fa/+ Zucker rats after
9 (for biochemistry) and 12 (for histology) months of chronic treatment
Lean vehicle Obese vehicle
Obese rimo
3 mg/kg/day
Obese rimo
10 mg/kg/day Obese pair-fed
Glucose (mmol/l) 4.3970.15 10.09#70.92 7.8070.46 7.19*70.31 8.2770.37
Insulin (ng/ml) 0.2270.03 0.59#70.07 0.7270.08 0.5770.09 0.8270.11
Glucagon (ng/ml) 0.6270.03 1.09#70.08 0.9170.08 0.9170.11 0.71*70.06
Pancreas weight (g) 1.5270.05 2.02#70.09 1.70*70.06 1.49*70.07 1.71*70.08
b-Cell mass index (FA per TA per PW)a 0.2270.04 0.06#70.01 ND 0.22*70.05 ND
b-Islets number (IN per TA per PW)a 1773 8#71 ND 25*78 ND
n 11–24 14–28 14–18 11–20 12–17
FA, fluorescent area; IN, b-Islets number, PW, pancreas weight; TA, tissue area.
*Po0.05 vs obese vehicle.
#Po0.05 vs lean vehicle.
Statistical analysis for b-cell mass index and b-islet number were performed by Kruskal–Wallis test. Plasma glucose, insulin and glucagon levels, and pancreas weight were
analyzed by one-way analysis of variance followed by a Newman–Keuls post hoc test.
aFA of insulin positive cells/TA/PW, b-islets number/TA/PW.
Lean fa /+ Zucker—vehicle Obese fa /fa Zucker—vehicle
Obese fa /fa Zucker— rimonabant 10 mg/kg/day
Figure 5 | Representative examples of pancreatic b-islet structure
revealed by insulin immunostaining. (a) Normal b-islet in lean
fa/þ Zucker rats, (b) fragmentation of b-islet structure in obese
fa/fa Zucker rats, and (c) preservation of b-islet integrity in
rimonabant-treated (10 mg/kg/day) obese fa/fa Zucker rats. Original
magnification  200.
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group also displayed a reduction in proteinuria but to a lesser
extent than the group treated with rimonabant at 10 mg/kg/
day. Urinary excretion rate of N-acetyl-glucosaminidase, a
marker of tubular injury, was significantly increased in obese
Zucker rats, and this elevation was markedly reduced by
rimonabant treatment (Figure 8). Both long-term treatment
with rimonabant and pair-feeding protocol prevented the
elevation in plasma creatinine and urea levels, and improved
the level of creatinine clearance significantly (Figure 9).
Reverse transcriptase-polymerase chain reaction experi-
ments indicated that CB1 receptor mRNA is expressed at a
low level with a Ct of about 33 in the kidney of obese fa/fa
Zucker rats with no difference in comparison with lean
control. This result was confirmed by immunohistochemistry
analysis (Figure 10), which revealed a distinct immuno-
reactivity for CB1 receptors in glomeruli and tubular epithelial
cells. In intrarenal arteries, CB1 receptor immunostaining
was restricted to the endothelium and was totally absent in
medial layers. Again no difference was observed in the pattern
and in the intensity of CB1 receptor immunostaining
between lean and obese Zucker rats (data not shown).
Histological analysis of kidney cross-sections revealed
severe glomerular and tubulointerstitial lesions including
glomerulosclerosis, tubular casts, dilatation, and atrophy, as
well as interstitial fibrosis in vehicle-treated obese fa/fa
Zucker rats in comparison with lean fa/þ Zucker rats
(Figures 11 and 12). Only rimonabant at 10 mg/kg/day
decreased significantly the severity of both glomerular and
tubulointerstitial lesions and reduced renal hypertrophy
(Figure 13). The development of glomerular fibrosis that
was detected in obese fa/fa Zucker rats was blunted both by
rimonabant and pair-feeding (Figure 13). Concordantly,
plasma plasminogen activator inhibitor 1 (PAI-1) levels that
were significantly elevated in untreated-obese fa/fa rats were
corrected by rimonabant treatment (Figure 13).
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Figure 6 | Effects of rimonabant, 3 and 10 mg/kg/day p.o., and
pair-feeding, on plasma norepinephrine in obese fa/fa Zucker
rats in comparison with control lean fa/þ Zucker rats after 9
months of chronic treatment. Values are expressed as
means7s.e.m. Statistical analysis was performed using Kruskal–Wallis
test. *Po0.05 vs vehicle-treated obese fa/fa Zucker rats.
Table 2 | Effects of rimonabant (3 and 10 mg/kg/day) and pair-feeding on hemodynamics in anesthetized obese fa/fa Zucker
rats in comparison with control lean fa/+ Zucker rats after 12 months of chronic treatment
Lean vehicle Obese vehicle
Obese rimo
3 mg/kg/day
Obese rimo
10 mg/kg/day Obese pair-fed
MAP (mm Hg) 9774 11079 11478 10677 11477
HR (bpm) 37477 388715 380714 396710 373712
SAP (mm Hg) 14075 171710# 17277 15678 169710
LVP (mm Hg) 14275 160711 17275 16376 163710
dP/dt max (mm Hg/s) 11 3377619 11 62571261 13 5557528 11 8317583 11 2477761
dP/dt min (mm Hg/s) 75157323 65537301 84327333 75367597 73337711
Cardiac index (ml/min/kg) 313722 255728 284724 231712 291729
RBF (ml/min/g) 3.070.2 1.370.2# 1.370.1 1.470.2 1.570.3
HW/BW (g/100 g) 0.4670.01 0.5270.03 0.5170.03 0.4970.02 0.4770.03
n 21–24 11–13 12–15 16–18 13–14
HR, heart rate; HW/BW, heart weight/body weight ratio; LVP, left ventricular pressure; MAP, mean arterial pressure; RBF, renal blood flow; SAP, systolic arterial pressure.
Hemodynamics was analyzed by one-way ANOVA followed by a Newman–Keuls post hoc test.
#Po0.05 vs lean vehicle.
Lean fa /+—vehicle (n=21)
Obese fa /fa—vehicle (n=11)
Obese fa /fa— rimonabant: 3 mg/kg/day (n=12)
Obese fa /fa— rimonabant: 10 mg/kg/day (n=16)
Obese fa /fa—pairfed (n=13)
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Figure 7 | Effects of rimonabant, 3 and 10 mg/kg/day p.o., and
pair-feeding, on pressor response to angiotensin II injected
intravenously at 30 and 100 ng/kg in anesthetized obese fa/fa
Zucker rats in comparison with control lean fa/þ Zucker rats
after 12 months of chronic treatment. Values are expressed as
means7s.e.m. Statistical analysis was performed using two-way
ANOVA followed by a Newman–Keuls post hoc test. *Po0.05 vs
vehicle-treated obese fa/fa Zucker rats; #Po0.05 rimonabant 10 mg/kg
vs pair-feeding.
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DISCUSSION
Obesity is considered to be a major public health problem as
it is recognized to predispose to diabetes, cardiovascular, and
end-stage renal disease, and to be associated with a higher
mortality rate. Obese patients are prone to glomerulopathy
including focal segmental glomerusclerosis and glomerular
hypertrophy.21 In line with these observations, patients with
pre-existing renal disease appeared to be vulnerable specially
to the harmful consequences of obesity, which could lead to
an accelerated loss of renal function.22 Accordingly, hypo-
caloric diet-induced body weight loss promoted a significant
reduction in proteinuria in obese patients with chronic
nephropathies.23 Several factors may contribute to the
pathogenesis of obesity-related renal failure including
glomerular hyperfiltration, hyperlipidemia, insulin resistance,
adipocyte-derived hormones (i.e. leptin), and systemic
inflammation.23,24
Recently, both experimental and clinical studies have
underlined the critical role of the endocannabinoid system in
the development of obesity. Chronic blockade of CB1
receptors by rimonabant in preclinical studies promoted a
sustained reduction in body weight along with a significant
improvement in the metabolic abnormalities related to
obesity.12,15 However, the long-term benefits of rimonabant
on renal function and survival in obese animals remained
unknown and are addressed in this study.
As expected, fa/fa Zucker rats displayed a marked obesity
and hyperphagia in comparison with age-matched fa/þ
Zucker rats. In this strain, as in other genetically obese
animals, defective leptin signaling is associated with an
increased endocannabinoid tone, which contributes to over-
eating and obesity.25 Although rimonabant at 3 mg/kg/day
caused a transient reduction in food intake, it did not reduce
significantly the body weight gain. The effect of rimonabant
on body weight was significant at 10 mg/kg/day with a rapid
onset (1 week) after initiating the treatment, and remained
sustained until the general status of control fa/fa Zucker rats
began to deteriorate with body weight loss and reduction in
appetite. These results were in agreement with previous
reports, indicating that the effect of rimonabant on body
weight was coupled with a temporary hypophagia.12,15 In the
vehicle-treated obese group, the secondary decline in body
weight and food intake occurred concomitantly with the
onset of death. Indeed, obese fa/fa Zucker rats started to die
rapidly after 9 months of follow-up with a mortality rate of
64% at 12 months in comparison with 4% monitored in the
control lean fa/þ Zucker rats. The shortened longevity of
obese fa/fa Zucker rats was caused by the development of a
severe renal failure, this result being in line with the
literature. At 12 months, they exhibited a significant renal
hypertrophy, a marked elevation in plasma creatinine and
urea levels, and a decrease in creatinine clearance. Protein-
uria, a marker of glomerular injury, rose dramatically over the
time course of this study. Histological analysis indicated that
untreated obese rats displayed glomerular and tubulointer-
stitial injuries, including glomerular enlargement, glomer-
ulosclerosis, collapsing of the glomerular tuft, and at the
tubule level, cast formation, dilatation, atrophy, and
inflammatory infiltrates. Accordingly, the urinary excretion
rate for N-acetyl-glucosaminidase, a marker of tubular injury,
was significantly increased in obese fa/fa Zucker rats relative
to lean littermates. Long-term treatment with rimonabant, at
both doses tested, prolonged markedly the life span of fa/fa
Zucker rats. A beneficial effect on mortality was evident even
at 3 mg/kg/day, a dose that did not significantly modify the
development of obesity in this strain. This beneficial effect
occurred in parallel with a delay in the progression of renal
failure. The increase in proteinuria was prevented by
rimonabant together with an improved creatinine clearance
and a reduction in glomerular injury and renal hypertrophy.
In addition, rimonabant limited the severity of tubulointer-
stitial lesions, a result in line with the reduction in excretion
rate for N-acetyl-glucosaminidase.
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Figure 8 | Effects of rimonabant, 3 and 10 mg/kg/day p.o., and
pair-feeding, on the (a) proteinuria/creatininuria ratio
(b) N-acetyl-glucosaminidase excretion rate in obese fa/fa Zucker
rats in comparison with control lean fa/þ Zucker rats after 1, 3,
6, 9, and 12 months of chronic treatment. Values are expressed as
means7s.e.m. Statistical analysis was performed using Kruskal–Wallis
test. The reduction in proteinuria/creatininuria ratio produced by
rimonabant was significant (Po0.05) up to 9 and 12 months of
treatment at 3 and 10 mg/kg/day, respectively. Prevention in the
elevation of N-acetyl-glucosaminidase excretion by rimonabant
remained significant up to 9 months for both doses. Pair-feeding was
effective up to 9 months on proteinuria/creatininuria ratio and on
N-acetyl-glucosaminidase excretion rate. *Po0.05 rimonabant
10 mg/kg vs obese fa/fa-vehicle; #Po0.05 rimonabant 3 mg/kg vs
obese fa/fa-vehicle; yPo0.05 pair-feeding vs obese fa/fa-vehicle;
$Po0.05 rimonabant 10 mg/kg vs pair-feeding.
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Reverse transcriptase-polymerase chain reaction and
immunohistochemistry experiments performed in this study
revealed a low expression of renal CB1 receptors, suggesting
that a putative overactivation of the endocannabinoid system
at the kidney level would result, if any, either in an increase in
circulating endocannabinoids and/or in an enhanced recep-
tor signaling in obese Zucker rats. Although the role of renal
CB1 receptors is still unknown, we cannot exclude that their
activation might contribute to the progression of renal failure
in obese Zucker rats.
The mechanism of the renoprotection afforded by
rimonabant might be also indirect in origin and could result
from the correction of the metabolic disorders. Lipid
abnormalities including high plasma cholesterol and trigly-
cerides levels have been considered to contribute to the
progression of renal failure in clinical studies. In this respect,
statins have been shown to correct hypercholesterolemia and
to improve renal function in diabetic patients with
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Figure 9 | Effects of rimonabant, 3 and 10 mg/kg/day p.o., and pair-feeding, on the (a) plasma creatinine, (b) plasma urea nitrogen,
(c) creatinine clearance in obese fa/fa Zucker rats in comparison with control lean fa/þ Zucker rats after 12 months of chronic treatment.
Values are expressed as means7s.e.m. Statistical analysis was performed using Kruskal–Wallis test. *Po0.05 vs vehicle-treated obese fa/fa
Zucker rats.
Figure 10 | Representative examples of CB1 receptor
immunostaining in obese fa/fa Zucker rats. (a) Glomerulus
showing a positive focal immunostaining for CB1 receptors.
(b) Tubules of the renal medulla did not display any CB1 receptor
immunoreactivity. (c) Positive control for CB1 receptor
immunostaining found in the brain.
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Figure 11 | Representative examples of glomerular structure.
(a) Normal glomeruli in lean fa/þ Zucker rats, (b) severe diffuse
glomerulosclerosis in obese fa/fa Zucker rats, and (c) less severe
glomerulosclerosis with focal pattern in rimonabant-treated
(10 mg/kg/d) obese fa/fa Zucker rats. Masson’s trichrome. Original
magnification  400. (d) The effects of rimonabant, 3 and 10 mg/kg/
day p.o., and pair-feeding, on glomerular lesions in obese fa/fa
Zucker rats in comparison with control lean fa/þ Zucker rats after 12
months of chronic treatment. Values are expressed as means7s.e.m.
Statistical analysis was performed using one-way ANOVA followed by
Newman–Keuls post hoc test. *Po0.05 vs vehicle-treated obese fa/fa
Zucker rats; #Po0.05 rimonabant 10 mg/kg vs pair-feeding.
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dyslipidemia.26,27 Dyslipidemia has also been reported to
elicit a deterioration of the renal function in several animal
models including B6.ROP Os/þ mice, a model with reduced
renal mass,10 obese fa/fa Zucker rats,11,28 and apolipoprotein
E knockout mice.9 At the glomerular level, mesangial cells
bind and take up native and oxidized LDL, triggering cellular
proliferation, cytokine production, and matrix deposi-
tion.29–31 As reported previously in diet-induced obese
mice,15 long-term treatment with rimonabant improved
markedly the lipid disorders in obese fa/fa Zucker rats with
a near normalization of the lipid profile, and in particular
total correction of the LDL/HDL ratio. Similarly, in over-
weight or obese patients, chronic blockade of CB1 receptors
by rimonabant combined with a hypocaloric diet produced a
sustained decrease in body weight, waist circumference, and
plasma triglycerides levels, together with an increase in HDL-
cholesterol levels and a shift toward less atherogenic LDL
particles.17,18 Therefore, the beneficial effects of rimonabant
on lipid metabolism may participate in the preservation of
the renal function and hence the prolonged life span observed
in obese fa/fa Zucker rats.
In addition, since chronic blockade of angiotensin AT1
receptors have been shown to correct metabolic disorders, to
prevent the development of renal failure, and consequently to
prolong survival of obese fa/fa Zucker rats,32,33 we investi-
gated whether long-term treatment with rimonabant could
modify angiotensin II-mediated responses in this strain.
Interestingly, we found that the pressor response to
exogenous angiotensin II was enhanced in obese animals
relative to lean controls, and was normalized by rimonabant
treatment. This increased pressor response to angiotensin II
has been previously documented in the obese Zucker
rats.34,35 The nature of the cross-talk between the CB1
receptor and the AT1 receptor is so far unclear, but could also
be possibly indirect in origin. For example, expression of
vascular AT1 receptors increased in parallel with LDL levels
in hypercholesteromic patients.36 Therefore, one might
speculate that rimonabant, by correcting hypercholesterol-
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Figure 12 | Representative examples of tubulointerstitial
structure. (a) Normal tubules and absence of fibrosis and
inflammation in the interstitium in lean fa/þ Zucker rats, (b) tubular
lesions characterized by tubular dilatation and casts (arrows)
associated with interstitial fibrosis and inflammation in obese fa/fa
Zucker rats, and (c) less intense tubulointerstitial lesions in
rimonabant-treated (10 mg/kg/day) obese fa/fa Zucker rats. Masson’s
trichrome. Original magnification  400. (d) The effects of
rimonabant, 3 and 10 mg/kg/day p.o., and pair-feeding, on
tubulointerstitial lesions in obese fa/fa Zucker rats in comparison with
control lean fa/þ Zucker rats after 12 months of chronic treatment.
Values are expressed as means7s.e.m. Statistical analysis was
performed using Kruskal–Wallis test. *Po0.05 vs vehicle-treated
obese fa/fa Zucker rats.
0
20
40
60
80
PA
I-I
 (n
g/m
l)
∗
∗
0
10
20
G
lo
m
er
ul
ar
 fi
br
os
is 
(%
) 30
∗ ∗
1.5
2
2.5
3
Ki
dn
ey
 w
ei
gh
t (g
)
∗
Lean fa /+—vehicle (n=21–24)
Obese fa /fa—vehicle (n=18–19)
Obese fa /fa— rimonabant: 3 mg/kg/day (n=18–19)
Obese fa /fa— rimonabant: 10 mg/kg/day (n=14–21)
Obese fa /fa—pairfed (n=12–17)
Figure 13 | Effects of rimonabant, 3 and 10 mg/kg/day p.o., and pair-feeding, on the (a) glomerular fibrosis (%), (b) plasma PAI-I levels,
(c) kidney weight in obese fa/fa Zucker rats in comparison with control lean fa/þ Zucker rats after 12 months of chronic
treatment. Values are expressed as means7s.e.m. Statistical analysis for glomerular fibrosis and plasma PAI-1 levels was performed by
Kruskal–Wallis test. Kidney weight was analyzed by one-way ANOVA followed by a Newman–Keuls post hoc test. *Po0.05 vs vehicle-treated
obese fa/fa Zucker rats.
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emia, could reduce vascular expression of AT1 receptors and
hence the pressor response to angiotensin II.
The renoprotection provided by rimonabant is unlikely to
be related to hemodynamic changes as neither renal blood
flow, arterial pressure, nor cardiac hemodynamics were
modified by a 12-month treatment with rimonabant. In
agreement with previous reports,37–39 obese Zucker rats
displayed a moderate systolic hypertension and an elevated
sympathetic nervous activity as illustrated by a significant
increase in plasma norepinephrine levels relative to lean
controls. Unlike pair-feeding, rimonabant was very effective
in correcting this elevation in circulating norepinephrine
levels. This increase in catecholamines was probably com-
pensatory in nature and might occur in response to a
decrease fatty acid oxidation capacity, which deteriorates
with aging and contributes to triglyceride accumulation in
skeletal muscle and liver of Zucker rats.40,41 Restoration of
fatty acid oxidation and reduction of fatty acid synthesis by
rimonabant42,43 could potentially be responsible for the
normalization of circulating norepinephrine levels observed
in this study.
PAI-1 is a key player in the fibrogenic process leading to
glomerulosclerosis, and elevated PAI-1 levels have been
documented in patients with obesity, type II diabetes, or
hypertension, and correlated with albuminuria.44,45 Geneti-
cally obese rodents (ob/ob mice, fa/fa Zucker rats) displayed
elevated plasma PAI-1 levels associated with high tissue
expression in adipose tissue, vessels, heart, liver, and
kidney.32,46,47 PAI-1 inhibits fibrinolysis, but also plasmin-
mediated matrix metalloproteinase activation, leading to
extracellular matrix accumulation and fibrosis. Upregulation
of PAI-1 synthesis has been reported in human diabetic
nephropathy and focal segmental glomerulosclerosis (for
review see Rerolle et al.48). Oxidized LDL induced PAI-1
promoter activity through autocrine activation of TGF-b
signaling in human mesangial cells.49 Elevation in plasma
PAI-1 levels has been shown to be correlated with the degree
of liver steatosis and adiposity.47 Increased plasma-free fatty
acid levels could possibly increase circulating PAI-1 in obese
fa/fa Zucker rats since a free fatty acid response element has
been identified and localized in the PAI-1 promoter.50 Thus,
chronic hyperlipidemia could promote the progressive
increase in plasma PAI-1 levels, hence contributing, at least
in part, to the development of renal failure. Therefore, the
mechanism by which rimonabant lowered plasma PAI-1
levels might be indirect and could result from the correction
of dyslipidemia (decrease in LDL-cholesterol and free fatty
acids) and from the reduction in fat mass, as weight loss in
obese patients leads to a notable decrease in circulating PAI-
1.51 This effect on plasma PAI-1 levels fitted with the
reduction in glomerular fibrosis observed in the rimonabant-
treated group.
The reduction in dyslipidemia produced by rimonabant
treatment might be ascribed to induction of lipolysis in
adipose tissue in parallel with an increased energy expendi-
ture.42 CB1 receptors are expressed in adipocytes and regulate
directly the plasma levels of adiponectin,14 an adipocyte-
derived hormone that promotes fatty acid b-oxidation, and
lipoprotein lipase activity.52 Plasma adiponectin levels are
depressed in obesity and have been reported to be increased
by rimonabant, both in experimental and clinical set-
tings.14,15,18 In this study, although rimonabant produced a
dose-dependent increase in plasma adiponectin concentra-
tions at 6 months, this effect did not reach statistical
significance after 9 months of treatment. Interestingly, we
found that plasma adiponectin levels doubled between 6 and
9 months in untreated obese fa/fa Zucker rats, which could
be related to the progression of chronic renal failure. Indeed,
plasma adiponectin levels are elevated in patients with
chronic renal disease due to a reduction in glomerular
filtration rate.53 This elevation, which coincided with a
deterioration of the renal function and hence the onset of
mortality, could be potentially responsible for the attenuation
of rimonabant-induced adiponectin synthesis.
Besides adipose tissue, it is probable that rimonabant also
targets the liver to ameliorate lipid abnormalities in obese
animals. CB1 receptors are expressed by hepatocytes and
upon activation they promote fatty acid synthesis through
the induction of the expression of the lipogenic transcription
factor SREBP-1c and its downstream target enzymes, acetyl
coenzyme-A carboxylase-1 and fatty acid synthase.43 More-
over, high-fat diet not only upregulated CB1 receptors in the
liver, but increased the hepatic levels of the endocannabinoid
anandamide due to a reduction in activity of fatty acid
amidohydrolase, the enzyme responsible for its catabolism.43
At 13 months of age, glycemia and hyperinsulinemia were
moderately elevated in obese Zucker rats. These results were
in agreement with previous reports in old Zucker rats,33,54
although considerable variability in glucose homeostasis has
been indicated for this animal model depending on the origin
of the strain, the age, the regimen, and the fasting conditions.
In contrast with experimental and clinical studies demon-
strating the beneficial effects of rimonabant treatment on
insulin resistance,12,15,17 we did not observe a reduction in
fasting plasma insulin levels by rimonabant (3 or 10 mg/kg/
day) or pair-feeding in old obese Zucker rats. This lack of
efficacy could be potentially attributed to a hyperinsulinemia,
which was too mild to be improved in this experimental
setting or to an inadequate time frame of measurement.
Indeed, fasting insulin levels are classically reported to be
increased by at least a 10-fold factor in young adult Zucker
rats.55,56 Both CB1 and CB2 receptors are expressed in the
islets of Langerhans.57 CB1 receptors are present mainly in
glucagon-secreting a-cells, whereas CB2 receptors are loca-
lized in both a- and b-cells. According to Juan-Pico et al.,57
activation of CB2 receptors and, to a less extent, CB1
receptors led to a decrease in insulin secretion. Nonetheless,
rimonabant treatment was very effective in preventing the
increase in pancreas weight and preserving the b-cell mass
index. To our knowledge, this is the first report of a beneficial
effect of chronic rimonabant treatment on endocrine
pancreatic structure. The decrease in b-cell mass index
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results from an alteration in the replication rate and/or the
death rate of b-cells. Since elevated free fatty acids have been
shown to promote b-cell apoptosis in obese Zucker rats,58,59
reduction in plasma free fatty acids levels by rimonabant
might contribute indirectly to its positive effects on pancreas
and b-cell mass index. Recently, a protective effect of CB1
antagonists on pancreas has been described by Matsuda
et al.60 using a model of pancreatitis.
The comparative analysis shown in Table 3 summarizes
the overall biological responses observed in the different
experimental groups. Table 3 underlines that the beneficial
effects of rimonabant were dose-dependent and that the
10 mg/kg/day dose improved all key parameters. Further-
more, rimonabant 10 mg/kg/day was overall superior to the
pair-feeding protocol. This global analysis indicates that the
sustained beneficial effects of rimonabant do not solely rely
on its effects on food intake. In comparison with the pair-fed
group, rimonabant 10 mg/kg/day shows greater effects on
survival rate, plasma triglycerides, nonesterified fatty acids,
adiponectin, glucose, PAI-1 and norepinephrine levels, the
exacerbated response to angiotensin II, proteinuria, renal
lesions, and hypertrophy. Our results, obtained after 12
months of treatment, contrast with the interpretation of
short-term favorable effects (4–14 days) of rimonabant,
which have been attributed principally to a decrease in food
intake.61 However, it is certainly possible that rimonabant-
induced changes in food intake and body weight are
significant factors in our study, and it would be interesting
to evaluate whether rimonabant could be beneficial in renal
failure unrelated to obesity.
In conclusion, we demonstrate that long-term treatment
with the CB1 receptor antagonist, rimonabant, in a rat model
of chronic renal failure related to metabolic abnormalities,
preserves renal function, reduces renal lesions, lowers body
weight, corrects lipid profile, and, ultimately, increases
survival.
MATERIALS AND METHODS
Animals
Male 12-week-old obese fa/fa Zucker rats and lean fa/þ Zucker rats
were purchased from Charles River Laboratories (St Germain sur
l’Arbresle, France). All animals were housed individually, with food
and water freely available, in an air-conditioned room (22721C)
and maintained under a 12-h light/dark cycle (light on 0700 hours).
Animals were fed ad libitum a standard laboratory chow (Dietex
M20, Saint Gracien, France). This study was performed in
accordance with the European Community Standards on the Care
and Use of Laboratory Animals and approved by the Animal Care
and Use Committee of Sanofi-Aventis Research & Development.
Experimental protocol
Twelve-week-old male obese fa/fa Zucker rats were treated with
either rimonabant (3 and 10 mg/kg/day per os (p.o.), n¼ 25/group)
or its vehicle (n¼ 50) for 12 months, and compared with a pair-fed
group (n¼ 25) receiving the same daily food intake as the group
treated with rimonabant at 10 mg/kg/day. Rimonabant was
incorporated with rodent diet (Dietex M20). Lean fa/þ Zucker
rats treated with the vehicle (n¼ 25) were included as a control to
evaluate the progression of the pathological state in obese fa/fa
Zucker rats. Body weight, food intake, and survival rate were
monitored weekly in each group.
Table 3 | Comparative analysis summarizing the effects of rimonabant at 3 and 10 mg/kg/day vs pair-feeding on obesity,
survival rate, metabolic, and renal parameters in obese fa/fa Zucker rats
Parameters Rimonabant 3 mg/kg/day Rimonabant 10 mg/kg/day Pair-fed
Body weight reduction No effect + +
Survival + + No effect
Triglycerides lowering effect + +,# +
Cholesterol lowering effect + + +
LDL-cholesterol lowering effect + + +
LDL-cholesterol/HDL-cholesterol lowering effect + + +
NEFA lowering effect No effect + No effect
Adiponectin 6 month increase + +,# +
Glucose lowering effect No effect + No effect
Pancreas weight reduction + + +
Norepinephrine lowering effect No effect + No effect
ANG II DMAP reduction No effect +,# No effect
Proteinuria reduction + +,# +
Urinary NAG reduction + + +
Plasma creatinine reduction + + +
Plasma urea reduction + + +
Creatinine clearance improvement + + +
Glomerular lesions reduction + +,# +
Tubular lesions reduction No effect + No effect
Glomerular fibrosis reduction No effect + +
Plasma PAI-1 reduction + + No effect
Kidney weight reduction No effect + No effect
ANG II, angiotensin II; LDL, low-density lipoprotein; MAP, mean arterial pressure; NAG, N-acetyl-glucosaminidase; NEFA; nonesterified fatty acids; PAI-1, plasminogen activator
inhibitor 1. No effect, no statistical significant effect; +statistical significant effect (Po0.05) vs obese vehicle; #statistical significant effect (Po0.05) vs obese pair-fed.
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Metabolic profile
After 9 months of chronic treatment, blood samples were collected
under fasted conditions (24 h) for biochemical analysis. Blood
collection was performed under isoflurane anesthesia on EDTA, and
plasma were separated by centrifugation (3000 g for 10 min at 41C)
and stored frozen (201C) until further processed. Plasma samples
were analyzed for glucose, total cholesterol, LDL, HDL, triglycerides
using a Cobas Mira Biochemical Analyzer (Roche, Basel, Switzer-
land), insulin (ELISA, Crystal Chem Inc., Chicago, IL, USA),
nonesterified fatty acids (colorimetric assay, WAKO Chemicals,
Neuss, Germany), glucagon (ELISA, WAKO Chemicals), adiponec-
tin (ELISA, B-Bridge International Inc., Mountain View, CA, USA),
and catecholamines (HPLC, C18 column, extraction kit and mobile
phase from Chromsystems, Mu¨nchen, Germany).
Renal function
Proteinuria was assessed every 3 months from urine samples
taken under fasted conditions (24 h). For this purpose, each
animal was placed individually in a metabolic cage for a 24-h
urine collection. After total urinary volume had been measured,
the urine was aliquoted, frozen (201C) and stored until
processed for the determination of proteins levels (Biome´rieux,
Marcy L’Etoile, France). In addition, at the end of the 12-month
treatment period, creatinine and urea nitrogen levels were quantified
in both plasma and urinary samples (ABX Diagnostics
kits, Montpellier, France), and creatinine clearance calculated.
Urinary N-acetyl-glucosaminidase level (colorimetric assay;
Roche), a marker of tubular injury, and plasma PAI-1 (ELISA,
Immuclone; American Diagnostic Inc., Stamford, CT, USA) were
also measured.
Hemodynamics
At the end of the treatment period, rats were anesthetized
(isoflurane 1.5%), and the right carotid artery and the left femoral
vein were catheterized for arterial pressure measurement and drug
administration, respectively. Hemodynamic recording was per-
formed using a data acquisition system (IOX software, EMKA
Technologies, Paris, France). To determine whether AT1 receptor
activity was altered by the chronic blockade of CB1 receptors,
the pressor response to intravenous bolus injection of angiotensin II
(30 and 100 ng/kg) was measured in the different groups.
Then the carotid catheter was advanced into the left ventricle to
monitor left ventricular pressure and end-diastolic left ventricular
pressure, and to calculate heart rate, maximal and minimal first
derivatives of developed pressure (dP/dtmax and dP/dtmin). To
measure regional blood flow and cardiac index, an additional
catheter was inserted into the left femoral artery. Animals were
administered a bolus injection of 400 000 fluorescent microspheres
(20 106/ml, 15 mm; Invitrogen, Cergy Ponroise, France) into the
left ventricle, followed by heparinized saline infusion at 2 ml/min
during 15 s. Simultaneously, femoral arterial blood withdrawal was
started at 1 ml/min during 45 s.
Animals were then euthanized and heart, kidneys, and pancreas
were rinsed by intra-arterial infusion of saline before being weighed,
frozen for microspheres processing, or fixed until further histo-
logical analysis. Microspheres were extracted by filtration after
potassium hydroxide digestion, dissolved in 2-ethoxyethyl acetate,
and fluorescence intensity was measured by spectrofluorimetry
(Safire II, Tecan, France). Renal blood flow, cardiac output, and
cardiac index were calculated according to Richer et al.62
Histology
Renal histology and molecular biology. Kidneys were long-
itudinally sectioned through the hilum and fixed in Bouin’s solution.
Paraffin-embedded renal tissue sections were stained with Masson’s
trichrome for semi-quantitative analysis. In each kidney, the vessels,
the glomeruli, the tubules, and the interstitium were systematically
analyzed. The following parameters were assessed: (1) in the
glomeruli—glomerulosclerosis, glomerular tuft collapsing, and
podocyte hyperplasia or droplet accumulation; (2) in the
tubules—casts, dilatation, and atrophy; (3) in the interstitium—
fibrosis and inflammatory infiltrates. A scoring system was used as
described previously.63,64 Briefly, a score 0 was given to a normal
glomerulus, a score 1 to any lesions involving less than 1/4 of the
tuft, a score 2 for less than 1/2, a score 3 for less than 3/4, and a score
4 for more than 3/4. In each rat, 100 glomeruli were scored at
original magnification  400. The glomerular lesion index was
calculated as follows: ((0 the number of normal glomeru-
li)þ (1 the number of score 1 glomeruli)þ (2 the number of
score 2 glomeruli)þ (3 the number of score 3 glomeru-
li)þ (4 the number of score 4 glomeruli))/100. For the cortical
tubulointerstitial component, a score 0 was given to a normal
microscopic field, a score 1 for any lesions involving less than 25%
of the microscopic field, a score 2 for less than 50%, a score 3 for less
than 75%, and score 4 for more than 75%. For each rat, 20
nonadjacent cortical microscopic fields were assessed at original
magnification  100. The tubulointerstitial lesion index was
calculated as above. Glomerular fibrosis was determined after
picrosirius red staining by quantitative analysis (MorphoExpert,
Explora Nova, France) on 50 glomeruli.
Total RNA was isolated from kidney samples of obese and lean
Zucker rats using RNeasy kit (Qiagen, Hilden, Germany). Purity was
assessed with a capillary electrophoresis Caliper Laboratory Chip
system (Agilent 2001 Bioanalyzer; Agilent Technologies, Waldbronn,
Germany). Quantitative duplex real-time polymerase chain reaction
was performed using QuantiTect Probe reverse transcriptase-
polymerase chain reaction 1-Step kit (Quiagen) and TaqMan Gene
Expression Assays (Applied Biosystems, Dormstadt, Germany) for
CNR1 and AGTR1 (both FAM/MGB probes) and for GAPDH (VIC/
MGB probe) as a control. Each sample was assessed in triplicate. For
relative quantification, the DDCT method was applied.
65
Immunohistochemistry for CB1 receptor was performed on
renal frozen 5 mm cross-sections from both obese fa/fa Zucker rats
and lean fa/þ Zucker controls using avidin–biotin peroxidase
method. Sections were incubated with a rabbit anti-mouse/rat CB1
receptor primary antibody (no. IMG-71170, Imgenex, San Diego,
CA, USA) diluted at 1/100, and then with biotinylated donkey anti-
rabbit IgG secondary antibody (1/200) (no. 711-065-152, Jackson,
Bar Harbor, Maine, USA). Following incubation with avidin–
peroxidase complex, immunostaining was revealed with a diamino-
benzidine and peroxide solution (no. 760124, DAB-MAP kit,
Ventana, Illkirch, France). The specificity of the immunostaining
was evaluated by performing negative control experiments in which
the primary antibody was substituted with a nonrelevant antibody.
Brain-frozen cross-sections from obese fa/fa Zucker rats were used
as positive control for CB1 receptor immunostaining.
Pancreas histology. b-Islet morphology was assessed after
insulin immunostaining of pancreas 10 mm cross-sections using an
anti-mouse monoclonal insulin antibody (1/1000 in 1%BSA–PBS—
0.1%Triton, ab6995, Abcam, TEBU, France), and revealed with a
goat anti-mouse IgG conjugated with FITC (1/100) as a secondary
antibody. The relative cross-sectional area of b-cells was determined
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by dividing insulin positive b-cell area by the total pancreas cross-
sectional area. The b-cells mass index was expressed as the ratio
between the relative cross-sectional area of b-cells and the pancreas
weight. Pancreatic b-islet number was determined after Heiden-
hain’s Azan staining.
Statistical analysis
Results are expressed as means7s.e.m. Survival rates were compared
by means of a log-rank test. On the basis of the normality of the
distribution and the homogeneity of variance (Levene test), one-way
analysis of variance (ANOVA) or two-way ANOVA was performed
using SAS version 8.2 software. This primary analysis was followed
by a Newman–Keuls post hoc test when appropriate. In case of non-
homogeneity of variance, Kruskal–Wallis test was applied. Diffe-
rences between groups were considered significant if Po0.05.
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